Protecting Products versus Platforms

Nature Biotechnology, Vol. 34, pp. 462-65

NYLS Legal Studies Research Paper No. 2789281

4 Pages Posted: 5 Jun 2016

See all articles by Jacob S. Sherkow

Jacob S. Sherkow

New York Law School; Columbia University - Department of Health Policy and Management; Center for Advanced Studies in Biomedical Innovation Law

Date Written: May 1, 2016

Abstract

Patents have long been the most important legal assets of biotech companies. Increasingly, however, biotech firms find themselves on one side of a divide: as either traditional product companies or platform companies. Given the differences between these two types of business models, the merits of intellectual property (IP) protection vary between them. This article explores how those differences relate to biotech startups and entrepreneurs seeking to protect their inventions.

Keywords: patents, trade secrets, intellectual property, biotechnology, startups

JEL Classification: K00, K23, K41, O3, O34, D23, K11

Suggested Citation

Sherkow, Jacob S., Protecting Products versus Platforms (May 1, 2016). Nature Biotechnology, Vol. 34, pp. 462-65; NYLS Legal Studies Research Paper No. 2789281. Available at SSRN: https://ssrn.com/abstract=2789281

Jacob S. Sherkow (Contact Author)

New York Law School ( email )

185 West Broadway
New York, NY 10013
United States
212.431.2355 (Phone)

HOME PAGE: http://www.nyls.edu/faculty/faculty-profiles/faculty_profiles/jacob-s-sherkow/

Columbia University - Department of Health Policy and Management ( email )

600 West 168th Street, 6th Floor
New York, NY 10032
United States

Center for Advanced Studies in Biomedical Innovation Law ( email )

Studiestraede 6
Studiestrade 6
Copenhagen, DK-1455
Denmark

HOME PAGE: http://jura.ku.dk/cebil/staff/

Register to save articles to
your library

Register

Paper statistics

Downloads
70
Abstract Views
313
rank
325,292
PlumX Metrics